Eli Lilly and Company

NYSE:LLY

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 684.73 B

Share Price

USD 762.73

Avg Daily Volume

4,188,687

Change (1 day)

-2.84%

Change (1 year)

-13.91%

Change (YTD)

-1.20%

Eli Lilly and Company Share Price Year-To-Date (YTD) return on June 20, 2025: -1.20%

Eli Lilly and Company Share Price Year-To-Date (YTD) return is -1.20% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Eli Lilly and Company 52-week low Share Price is USD 960.02 on June 20, 2025, which is 25.87% above the current Share Price.
Eli Lilly and Company 52-week low Share Price is USD 713.71 on June 20, 2025, which is -6.43% below the current Share Price.
Eli Lilly and Company average Share Price for the last 52 weeks is USD 837.17.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NYSE: LLY

Eli Lilly and Company

CEO	Mr. David A. Ricks
IPO Date	June 1, 1972
Location	United States
Headquarters	Lilly Corporate Center
Employees	47,000
Sector	🏥 Health Care
Industries Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.